Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

[News]

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

More... (http://www.news-medical.net/news/20120524/Preliminary-results-from-Celldexe28099s-CDX-011-Phase-2b-breast-cancer-study.aspx)